Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma | Synapse
March 3, 2026
Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma
BM
Brigida Anna Maiorano
ND
Nazli Dizman
The University of Texas MD Anderson Cancer Center
AN
Andrea Necchi
Vita-Salute San Raffaele University
Puntos clave
Advanced urothelial carcinoma shows promise with emerging anti-HER2 therapies, enhancing patient care.
Significant improvements in clinical outcomes noted for patients treated with these targeted therapies.
Comprehensive review of therapeutic development highlights the vital role of biomarkers for patient stratification.
Implications call for further research to validate these therapies and explore combination treatments.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Maiorano et al. (Sun,) studied this question.
synapsesocial.com/papers/69a7688fbadf0bb9e87e51b6
https://doi.org/https://doi.org/10.1016/j.eururo.2026.01.027